Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Heparin, Low-Molecular-Weight

Heparin, Low-Molecular-Weight

Heparin, Low-Molecular-Weight: Discover the power of PubCompare.ai's AI-driven platform to optimize your research protocols for this important class of anticoagulants.
Easily locate the best protocols from literature, pre-prints, and patents using our intelligent comparison tools.
Streamline your research and find the most effective solutions with PubCompare.ai's cutting-edg technology.
Reduce time and effort with our intuitive interface and data-driven insights.
Experince the future of research protocol optimization today.

Most cited protocols related to «Heparin, Low-Molecular-Weight»

1
Platelet Activation Assay for Vaccine-Induced Thrombosis
Cited 22 times
We purified platelets from whole blood (obtained from healthy volunteers) that had undergone anticoagulation with adenine citrate dextrose solution A. None of the volunteers had been taking antiplatelet drugs or had been vaccinated in the previous 10 days. We prepared platelets using methods that have been described previously.2 (link),3 (link) In a subgroup of experiments, platelets were preincubated in buffer with ChAdOx1 nCov-19 (1:2000 dilution) and washed before use. Washed platelets (75 microliters) were incubated with either buffer, a low-molecular-weight heparin (reviparin [Abbott]), or PF4 (Chromatec) in either the presence or absence of the FcγIIa receptor–blocking antibody IV.3. In some experiments, unfractionated heparin (100 IU per milliliter) was added to inhibit PF4-dependent reactions, or ChAdOx1 nCov-19 (1:50 dilution) was added per well. Serum was coincubated with PF4 and platelets in the presence of immune globulin (Privigen IVIG [CSL Behring]) at a concentration of 10 mg per milliliter. After establishing assay conditions using serum from the initial four patients, we investigated another 24 serum samples that tested positive on immunoassay to validate our findings. We refer to this modified platelet-activation test as the PF4-enhanced platelet-activation test.
To measure direct antibody binding, we used two immunoassays, a PF4–heparin enzyme-linked immunosorbent assay (ELISA) and a PF4 ELISA, with antibody binding measured by a secondary antihuman IgG, as described previously.4 (link) In addition, antibodies from two serum samples were affinity purified by immobilized PF4–heparin and immobilized PF4, and the purified antibodies were tested in the assays. (Details about this method are provided in the Supplementary Appendix, available with the full text of this article at NEJM.org.)
We defined reactivity on ELISA according to the optical-density units as strong (≥2.00), intermediate (1.00 to 1.99), or weak (0.50 to 0.99). On the PF4-enhanced platelet-activation test, reactivity was graded according to the time that had elapsed until platelet aggregation,5 (link) with shorter reaction times indicating stronger platelet activation (strong activation, 1 to 5 minutes; intermediate activation, >5 to 15 minutes; and weak activation, >15 to 30 minutes).
Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A, & Eichinger S. (2021). Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. The New England Journal of Medicine.
Publication 2021
Adenine Antibodies Antibodies, Blocking Antiplatelet Agents Biological Assay Blood Platelets Buffers Cardiac Arrest ChAdOx1 nCoV-19 Citrates Debility Enzyme-Linked Immunosorbent Assay Glucose Healthy Volunteers Heparin Heparin, Low-Molecular-Weight Immunoassay Immunoglobulins Intravenous Immunoglobulins Patients Platelet Activation Platelet Aggregation Privigen reviparin Serum Technique, Dilution Voluntary Workers
2
Coagulation Abnormalities in Severe COVID-19
Cited 19 times
Consecutive patients with severe COVID‐19 admitted to Tongji Hospital of Huazhong University of Science and Technology in Wuhan from January 1 to February 13, 2020, were retrospectively enrolled. Exclusion criteria were a bleeding diathesis, hospital stay < 7 days, lack of information about coagulation parameters and medications, and age < 18 years. A retrospective review of the characteristics of these patients was performed through the electronic medical record system of our hospital, the medications and outcomes (28‐day mortality) were monitored up to March 13, 2020. This study was approved by the Ethics Committee of Tongji Hospital (Wuhan, China).
The diagnosis of COVID‐19 was according to World Health Organization interim guidance8 and confirmed by RNA detection of the SARS‐CoV‐2 in a clinical laboratory of the Tongji hospital. Severe COVID‐19 was defined as meeting any one of following items, according to the Diagnosis and Treatment Plan of COVID‐19 suggested by National Health Commission of China9 : Respiratory rate ≥30 breaths/min; arterial oxygen saturation ≤93% at rest; PaO2/FiO2 ≤ 300 mm Hg.
The SIC score system including prothrombin time (PT), platelet count, and sequential organ failure assessment (SOFA) was described in Table 1,6 (link) in which the SOFA score contained four items and was originally developed by an international group of experts to describe the time course of muitiple organ dysfunctions using a limited number of routinely measured variables.10 (link) Meanwhile, in our previous study,3 (link) higher D‐dimer and PT on admission were associated with poor prognosis in patients with COVID‐19. Hence these three parameters were included in this study and the results were recorded at the time the patient meeting the definition of severe COVID‐19. Anticoagulant treatment group was defined as receiving unfractionated heparin or low molecular weight heparin (LMWH) for 7 days or longer,11 (link) which was the most commonly used anticoagulant therapy for COVID‐19 in our hospital.

ISTH SIC scoring system

Table 1
ItemScoreRange
Platelet count (×109/L)1100‐150
2<100
PT‐INR11.2‐1.4
2>1.4
SOFA score11
2≥2
Total score for SIC≥4

Abbreviations: INR, International Normalized Ratio; SOFA, sequential organ failure assessment.

The coagulation tests, including PT and D‐dimer, were detected using a STA‐R MAX coagulation analyzer and original reagents (Diagnostica Stago). The platelet counts were analyzed by a Sysmex XE‐2100 hematology analyzer (Sysmex).
Normally and abnormally distributed quantitative variables were compared using the Student's t‐test and the Mann‐Whitney U test, respectively. Categorical variables were compared using the chi‐squared test. The results were given as the mean ± standard deviation, median (interquartile range), or number (percentage), wherever appropriate. Categorical and consecutive variables were evaluated by logistic regression analysis for their ability to predict 28‐day mortality. A P value of < .05 was considered statistically significant. Data were analyzed using SPSS 21.0 for Windows (SPSS Inc).
Tang N., Bai H., Chen X., Gong J., Li D, & Sun Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis, 18(5), 1094-1099.
Publication 2020
Anticoagulants Arteries Blood Coagulation Disorders Coagulation, Blood COVID 19 Diagnosis Ethics Committees, Clinical fibrin fragment D Heparin Heparin, Low-Molecular-Weight International Normalized Ratio Oxygen Saturation Patients Pharmaceutical Preparations Platelet Counts, Blood Prognosis Respiratory Rate SARS-CoV-2 Tests, Blood Coagulation Therapeutics Times, Prothrombin
3
Undisplaced Hip Fractures: Surgical Outcomes
Cited 9 times
113 consecutive patients aged 60 years or older (mean age 78 (60–99) years, 82 women) were admitted to our department between September 2002 and November 2006 with Garden I–II fractures (undisplaced inferior cortical buttress (Garden 1961 )) treated in a fracture table by IF with 2 parallel implants: Olmed screws (Olmed Medical AB, Sweden) in 37 cases, and Hansson pins (Swemac Orthopaedics AB, Sweden) in 76 cases.
The patients followed the department's multimodal fast-track hip fracture program (Foss et al. 2005 (link)). They underwent daytime surgery using epidural anesthesia. Preoperatively, a single dose of 1.5 g cephalosporin was administered intravenously. Postoperatively, low-molecular-weight heparin was administered until full mobilization. Mobilization with full weight bearing was encouraged from the first day of surgery in a physiotherapy program with two daily sessions. Patients were scored according to the American Society of Anaesthesiologists Physical Grading Score (ASA 0–4) (American Society of Anaesthesiologists 1963 ), and Parker's New Mobility Score (NMS 0–9, where ≤ 5 designates inhibited functional level) (Parker and Palmer 1993 (link)). Patient's cognitive function was assessed with a Danish version of the abbreviated mental status test taken upon admission (Quereshi and Hodkinson 1974 (link)). The expertise of the surgeon was determined and scored as a junior registrar procedure or as senior surgeon procedure (Palm et al. 2007 (link)). Patient data were prospectively included in a database.
Radiographs were stored in the Image Management and Applications-Radiology Information Service (IMPAX-RIS) system (Agfa, Köln, Germany) and digitally measured retrospectively. Posterior tilt was determined in preoperative lateral radiographs as the angle between (1) the mid-collum line (MCL) and (2) the radius collum line (RCL) (Figure 1). MCL was drawn through the middle of 3 perpendicular lines across the collum; with 1 line drawn at the narrowest part of the collum, and 2 parallel lines drawn subsequently 5 mm apart on each side. RCL was drawn from the center of the caput circle to the crossing of the caput circle and the mid-collum line.
All measurements were assessed by the same observer (HP). For reliability reasons, an intra-and interobserver study was performed by 2 of the authors (HP and KG, who was junior orthopedics resident) on 50 randomly selected lateral radiographs with independent assessment of posterior tilt twice, 2 weeks apart. At the time of assessment, the observers were blinded regarding postoperative radiographs and which patients later required a reoperation.
All fractures remained undisplaced in the first postoperative AP radiograph and fracture reduction was therefore assessed purely as postoperative posterior tilt in the first postoperative lateral radiograph. Implant positioning was assessed from AP and lateral radiographs as the minimal perpendicular distance (in mm) from the implants to the outer cortex contrast line of (1) the calcar, and (2) the posterior cortex, both on the femoral shaft side of the fracture.
Reoperations within 1 year were registered from patient records and cross-checked with the Copenhagen radiological database for admission due to complications to hip surgery in other departments. Only reoperations due to technical failures—fracture displacement, nonunion, avascular necrosis, subsequent fractures round the implant, or cutout of implant from the femoral head—were assessed as outcome parameter. All patients were scheduled for a follow-up visit including radiographs at 6 weeks postoperatively. If delayed but possible signs of healing were observed, several radiographs were later performed. All patients with radiographs showing technical failures were reoperated.
The study was part of the hip fracture project at Hvidovre University Hospital, Copenhagen, Denmark. It was approved by the Danish data protection agency and Copenhagen ethics committee. The latter concluded that the nature of the study was such that written consent from patients was not required.
Palm H., Gosvig K., Krasheninnikoff M., Jacobsen S, & Gebuhr P. (2009). A new measurement for posterior tilt predicts reoperation in undisplaced femoral neck fractures: 113 consecutive patients treated by internal fixation and followed for 1 year. Acta Orthopaedica, 80(3), 303-307.
Full text: Click here
Publication 2009
Anesthesiologist Arecaceae Avascular Necrosis of Bone Cephalosporins Cognition Cortex, Cerebral Epidural Anesthesia Ethics Committees Femoral Fractures Femur Heads FOS protein, human Fracture, Bone Fracture Fixation Head Heparin, Low-Molecular-Weight Hip Fractures LINE-1 Elements Multimodal Imaging Neck Operative Surgical Procedures Orthopedic Surgical Procedures Patients Physical Examination Radius Range of Motion, Articular Repeat Surgery Second Look Surgery Surgeons Surgery, Day Therapy, Physical Woman X-Rays, Diagnostic
4
Andexanet Alfa for Reversal of Anticoagulation
Cited 8 times
Safety analyses included all the patients who had received andexanet. The efficacy analysis population included only patients who retrospectively met both of two criteria: baseline anti-factor Xa activity of at least 75 ng per milliliter (or ≥0.25 IU per milliliter for patients receiving enoxaparin) and confirmed major bleeding at presentation, as determined by the adjudication committee. Initially, a sample of 250 patients was planned, which would provide 80% power to show that the percentage of patients with excellent or good hemostatic efficacy was more than 50%. The sample was adjusted to 350 patients in protocol amendment 4 (January 2017) to meet new regulatory requirements for sufficient numbers of patients for each factor Xa inhibitor and to have at least 120 patients with intracranial hemorrhage in the efficacy analysis population.
Continuous variables are summarized as mean and standard deviation or median and interquartile range; categorical variables are presented as frequencies. Percent change from baseline in anti-factor Xa activity was computed with a two-sided nonparametric confidence interval for the median.10 Percentages of patients with effective hemostasis are presented with a 95% confidence interval calculated with the binomial test. The association between hemostatic efficacy and change in anti-factor Xa activity was examined with the use of receiver-operating-characteristic (ROC) curves.11 (link) Analyses were performed with the use of SAS software, version 9.4 (SAS Institute).
Connolly S.J., Crowther M., Eikelboom J.W., Gibson C.M., Curnutte J.T., Lawrence J.H., Yue P., Bronson M.D., Lu G., Conley P.B., Verhamme P., Schmidt J., Middeldorp S., Cohen A.T., Beyer-Westendorf J., Albaladejo P., Lopez-Sendon J., Demchuk A.M., Pallin D.J., Concha M., Goodman S., Leeds J., Souza S., Siegal D.M., Zotova E., Meeks B., Ahmad S., Nakamya J, & Milling TJ J.r. (2019). Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. The New England journal of medicine, 380(14), 1326-1335.
Publication 2019
andexanet Enoxaparin Factor Xa Factor Xa Inhibitors Hemostasis Heparin, Low-Molecular-Weight Intracranial Hemorrhage Patients Safety
5
Guidance on Venous Thromboembolism Management
Cited 7 times
To provide guidance on the management of VTE, the authors developed a list of important management questions to be considered in this document (Table 1). Questions were developed by consensus of all the authors. To answer these questions, a literature search of MEDLINE and EMBASE from January 2004 to August 2014 was conducted. The following search terms were used and combined: anticoagulant treatment, anticoagulant therapy, antithrombotic treatment, heparin, low molecular weight heparin, enoxaparin, nadroparin, dalteparin, certoparin, bemiparin, tinzaparin, parnaparin, reviparin, vitamin K antagonists, warfarin, acenocoumarol, phenprocoumon, thrombolysis, thrombolytic treatment, fibrinolytic agent, fibrinolysis, urokinase, tenecteplase, alteplase, rtPA, tPA; aspirin, ticlopidine, clopidogrel; venous thromboembolism, venous thrombosis, deep venous thrombosis, deep vein thrombosis, superficial venous thrombosis, superficial venous thrombophlebitis; diagnosis. The search strategy was restricted to papers published in English. Detailed information on the results of the literature search is available upon request.

Guidance questions to be considered

How is the diagnosis of deep vein thrombosis and pulmonary embolism established?
Which patients require hospitalization versus initial outpatient therapy for the management of VTE?
What are the therapeutic options for the acute treatment of venous thromboembolism?
Which patients are candidates for a DOAC?
What is the role of vena cava filters if the patient is not a candidate for anticoagulation?
How is upper extremity VTE treated?
When is ambulation/exercise safe after DVT/PE?
Is the use of graduated compression stockings safe after acute DVT/PE?
What is the recommended duration of therapy for VTE?   What is the recommended duration of therapy for a patient with distal DVT?   What is the recommended duration of therapy for a patient with a surgically provoked VTE?   What is the recommended duration of therapy for a pregnancy or estrogen-associated VTE?   What is the recommended duration of therapy for a medical illness-associated VTE?   What is the recommended duration of therapy for a travel-associated VTE?   What is the recommended duration of therapy for a malignancy-associated VTE?   What is the recommended duration of therapy for a patient with unprovoked DVT/PE?
What are the therapeutic options for long term treatment of DVT/PE?
What is the best treatment of patients who have recurrent VTE in spite of anticoagulation?
How can you assess the risk of recurrent VTE and anticoagulant-associated bleeding?
For papers published before 2004, we only considered the most important studies that were likely to influence our responses to the questions. These studies were selected and suggested by the authors of this guidance document.
Streiff M.B., Agnelli G., Connors J.M., Crowther M., Eichinger S., Lopes R., McBane R.D., Moll S, & Ansell J. (2016). Guidance for the treatment of deep vein thrombosis and pulmonary embolism. Journal of Thrombosis and Thrombolysis, 41, 32-67.
Full text: Click here
Publication 2016
Acenocoumarol antagonists Anticoagulants Aspirin bemiparin certoparin Clopidogrel Compression Stockings Dalteparin Diagnosis Enoxaparin Estrogens Fibrinolysis Fibrinolytic Agents Heparin Heparin, Low-Molecular-Weight Hospitalization Long-Term Care Malignant Neoplasms Nadroparin Operative Surgical Procedures Outpatients parnaparin Patients Phenprocoumon Pregnancy Pulmonary Embolism reviparin Tenecteplase Thrombophlebitis Ticlopidine Tinzaparin Upper Extremity Urokinase Veins Vena Cava Filters Venous Thromboembolism Venous Thrombosis Vitamin K Warfarin

Most recents protocols related to «Heparin, Low-Molecular-Weight»

1
Temporary IVC Filter and DVT Management
A temporary filter was inserted via the nonaffected femoral or jugular vein into the inferior vena cava (IVC) prior to the next procedure for patients with an extensive thrombus in the proximal vein that was evaluated as potentially life-threatening and was retrieved after the proximal DVT was removed and potentially life-threatening conditions were relieved. Consistent with local routines based on published guidelines [9 ], anticoagulant treatment was initiated immediately when DVT was identified with the use of subcutaneous low molecular weight heparin (LMWH) at a bolus dose of 100 units/kg twice daily. PTA and/or stent placement was encouraged for lesions that caused 50% or greater diameter narrowing of the iliac and/or common femoral vein, robust collateral filling, and/or a mean pressure gradient of more than 2 mmHg. At the end of LMWH, oral rivaroxaban was directly commenced at a dosage of 15 mg twice a day over the subsequent 21 days and 20 mg once a day thereafter for at least 6 months. In addition, the use of compression stockings (ankle pressure was approximately 30–40 mmHg) for more than 1 year was recommended.
Gong M., Fu G., Liu Z., Zhou Y., Kong J., Zhao B., Lou W., Gu J, & He X. (2023). Rheolytic thrombectomy using an AngioJet ZelanteDVT catheter or a Solent Omni catheter for patients with proximal vein thrombosis. Thrombosis Journal, 21, 25.
Full text: Click here
Publication 2023
Ankle Anticoagulants Compression Stockings Femur Heparin, Low-Molecular-Weight Ilium Jugular Vein Patients Pressure Rivaroxaban Stents Thrombus Vein, Femoral Veins Vena Cavas, Inferior
2
Comprehensive Coagulation Profile of Surgical Patients
The following coagulation assays (reagent and unit in parenthesis) in citrated (3.2%) plasma were analyzed at the local Central Coagulation Laboratory (HUSLAB of Helsinki University Hospital): FVIII (FVIII:C one-stage clotting assay [IU/dl], pathromtin SL and FVIII deficient plasma), fibrinogen (Clauss method [g/l], HemosIL Q.F.A.Thrombin, Werfen, Barcelona, Spain; D-dimer [mg/l] HemosIL D-Dimer HS 500), antithrombin (AT [%], a chromogenic assay Berichrom Antithrombin III), thrombin time ([s], BC Thrombin reagent, Siemens), activated partial thromboplastin time (APTT [s], Actin FSL®, Siemens) and anti-FXa activity (anti-FXa [IU/ml], HemosIL Liquis Anti-Xa, Mediq Suomi Oy). We acquired data of these coagulation markers preoperatively and from the days 1, 2, 3, 7, 14, 30, 90, and 12 months after the operation, if available.
In addition, we measured the dynamics of white blood cell (WBC) count, C-reactive protein (CRP, mg/l), and platelet count (109/l) from the same time points. Preoperative plasma values of prothrombin time (Medirox Owren's PT [%] Medirox, Nyköping, Sweden), FXIII (F-XIII, %), VWF antigen (VWF:Ag, %) and VWF glycoprotein GPIb binding activity (VWF:Act, %), homocysteine (Hcyst, µmol/l), low-density lipoprotein (mmol/l), and triglycerides (Trigly, mmol/l) were collected. Additionally, patients were screened for protein C and S deficiencies, antiphospholipid antibodies as well as Factor V Leiden and FII G20210A mutations.
Myllylahti L., Ropponen J., Lax M., Lassila R, & Nykänen A.I. (2023). Upregulation of Coagulation Factor VIII and Fibrinogen After Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 29, 10760296231158369.
Full text: Click here
Publication 2023
Actins Activated Partial Thromboplastin Time Antigens Antiphospholipid Antibodies Antithrombin III azo rubin S Biological Assay Coagulation, Blood C Reactive Protein factor V Leiden fibrin fragment D Fibrinogen Glycoproteins Heparin, Low-Molecular-Weight Homocysteine Leukocyte Count Low-Density Lipoproteins Mutation Patients Plasma Platelet Counts, Blood Protein C Tests, Blood Coagulation Thrombin Times, Prothrombin Times, Reptilase Triglycerides
3
Perioperative Antithrombotic Management for PEA
Before PEA, 8 patients were anticoagulated with warfarin, 6 with LMWH, 2 with fondaparinux and 1 with unfractionated heparin (UFH), and due to the thrombotic burden, 15 of 17 patients also received low-dose aspirin (ASA, 100 mg) and statins. ASA was withheld for 5 days prior to PEA. Postoperative anticoagulation was initiated by UFH (1 patient) or LMWH (dalteparin in 8, enoxaparin in 7, and tinzaparin in 1 patient) at 372 ± 177 min after surgery and ASA 2.8 ± 1.8 days after the operation. LMWH dosage was titrated until the targeted through anti-FXa activity of 0.2-0.5 IU/ml was achieved and switched to fondaparinux before discharge in 2 patients. At 3 months, 14 patients were treated with LMWH (9 with dalteparin and 5 with enoxaparin) and 2 patients with fondaparinux, and 16 patients received ASA. The long-term antithrombotic care and the switch to oral anticoagulation with warfarin was later determined on individual basis.
Myllylahti L., Ropponen J., Lax M., Lassila R, & Nykänen A.I. (2023). Upregulation of Coagulation Factor VIII and Fibrinogen After Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension. Clinical and Applied Thrombosis/Hemostasis, 29, 10760296231158369.
Full text: Click here
Publication 2023
Dalteparin Enoxaparin Fondaparinux Heparin Heparin, Low-Molecular-Weight Hydroxymethylglutaryl-CoA Reductase Inhibitors Long-Term Care Operative Surgical Procedures Patient Discharge Patients Surgery, Day Tinzaparin Warfarin
4
Coagulopathy and Thrombosis in COVID-19

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Activated Partial Thromboplastin Time Antithrombin III Continuous Positive Airway Pressure COVID 19 C Reactive Protein Disseminated Intravascular Coagulation Factor VIII Factor VIII-Related Antigen Fibrinogen Hemoglobin Heparin Heparin, Low-Molecular-Weight Index, Body Mass International Normalized Ratio Protein C Protein S SARS-CoV-2 Times, Prothrombin Veins
5
Thromboprophylaxis for Arthroplasty Patients
As the SFK holds no surgery dates, a proxy variable had to be identified. Thrombophylactic drugs, prescribed within a two-week time window of the surgery date (4 days before surgery-10 days after surgery), were chosen as all arthroplasty patients routinely receive thromboprophylaxis after knee/hip arthroplasty surgery to prevent thrombotic events [12 ]. The first and second choices for thromboprophylaxis after arthroplasty are low-molecular-weight heparin (LMWH) and direct-oral anticoagulants (DOACs), both were used for linkage (Table 2).
van Brug H.E., Rosendaal F.R., van Steenbergen L.N., Nelissen R.G, & Gademan M.G. (2023). Data linkage of two national databases: Lessons learned from linking the Dutch Arthroplasty Register with the Dutch Foundation for Pharmaceutical Statistics. PLOS ONE, 18(3), e0282519.
Full text: Click here
Publication 2023
Anticoagulants Arthroplasty Heparin, Low-Molecular-Weight Knee Replacement Arthroplasty Operative Surgical Procedures Patients Pharmaceutical Preparations

Top products related to «Heparin, Low-Molecular-Weight»

1
Clexane by Sanofi
Sourced in France, Spain, Italy, United Kingdom, Belgium
Clexane is a laboratory equipment product designed for the measurement and analysis of various samples. It is a compact and versatile device that can perform a range of analytical functions.
2
Sta liquid anti xa by Diagnostica Stago
Sourced in France
The STA®-Liquid Anti-Xa is a laboratory equipment product manufactured by Diagnostica Stago. It is used for the quantitative determination of heparin (unfractionated and low molecular weight) and fondaparinux in plasma samples.
3
Enoxaparin by Sanofi
Sourced in France, China, Germany, United States, Belgium
Enoxaparin is a low-molecular-weight heparin (LMWH) that is used as an anticoagulant. It is a sterile, clear, colorless to pale yellow, aqueous solution that is administered by subcutaneous injection.
4
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
5
Rivaroxaban by Bayer
Sourced in Germany, France
Rivaroxaban is a pharmaceutical product used in laboratory settings. It functions as an oral anticoagulant medication, inhibiting the coagulation factor Xa. This direct factor Xa inhibitor helps regulate blood clotting processes in research and testing environments.
6
Fragmin by Pfizer
Sourced in United States, United Kingdom
Fragmin is a laboratory product manufactured by Pfizer. It is an anticoagulant medication used to prevent and treat blood clots. The core function of Fragmin is to inhibit the formation of blood clots.
7
Cs2100i by Sysmex
Sourced in Japan, United Kingdom, France, Germany
The CS2100i is a compact and fully automated coagulation analyzer designed for clinical laboratories. It performs a range of coagulation tests, including prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen. The CS2100i features a user-friendly interface and is capable of handling a variety of sample types, providing reliable and efficient coagulation testing.
8
Enoxaparin sodium by Sanofi
Sourced in France
Enoxaparin sodium is a low-molecular-weight heparin used as an anticoagulant. It is a sterile, clear, colorless to yellowish-brown, and odorless solution. The active ingredient is a sodium salt of a sulfated polysaccharide extracted from porcine intestinal mucosa.
9
Low molecular weight heparin by Merck Group
Sourced in United States
Low molecular weight heparin is a type of anticoagulant medication. It is derived from the natural substance heparin and has a smaller molecular size. Low molecular weight heparin acts to inhibit specific clotting factors, thereby reducing the risk of blood clot formation.
10
Sta liquid anti xa by Stago
Sourced in France
The STA®-Liquid Anti-Xa is a lab equipment product used for the quantitative determination of anti-Xa activity in plasma. It is designed to measure the anticoagulant effect of heparin and other anti-Xa agents.

More about "Heparin, Low-Molecular-Weight"

Heparin, Low-Molecular-Weight (LMWH) is a class of anticoagulant medications used to prevent and treat various thromboembolic disorders.
These agents, also known as low-molecular-weight heparins, are derived from standard unfractionated heparin through chemical or enzymatic depolymerization.
This process results in shorter polysaccharide chains with a reduced average molecular weight, typically ranging from 2,000 to 8,000 Daltons.
LMWH medications, such as Clexane (enoxaparin), STA®-Liquid Anti-Xa, and Fragmin (dalteparin), offer several advantages over unfractionated heparin, including improved bioavailability, more predictable dose-response, and a lower risk of heparin-induced thrombocytopenia.
These properties make LMWH a preferred anticoagulant choice for a variety of clinical scenarios, including deep vein thrombosis (DVT) prophylaxis, treatment of acute coronary syndromes, and management of venous thromboembolism (VTE).
The effectiveness and safety of LMWH have been extensively studied, with numerous clinical trials and research protocols evaluating their performance.
PubCompare.ai's AI-driven platform can help researchers optimize their research protocols for LMWH by providing intelligent comparison tools to locate the best protocols from literature, preprints, and patents.
This cutting-edg technology can streamline the research process, reduce time and effort, and deliver data-driven insights to find the most effective solutions.
Whether you're investigating the pharmacokinetics of LMWH, exploring the use of Enoxaparin sodium in combination with Rivaroxaban, or evaluating the impact of Fragmin on FBS levels, PubCompare.ai's intuitive interface and innovative features can enhance your research efforts and help you experince the future of protocol optimization today.